Literature DB >> 2512139

Successful treatment with liposomal amphotericin B in two patients with persisting fungemia.

J P Sculier1, D Bron, A Coune, F Meunier.   

Abstract

Two granulocytopenic patients in whom fungemia persisted despite therapy with deoxycholate amphotericin B were subsequently successfully treated by daily intravenous administration of amphotericin B entrapped in sonicated liposomes made of egg yolk lecithin, cholesterol and stearylamine in a molar ratio of 4:3:1. High serum concentrations of amphotericin B could be maintained in both patients during therapy with liposomal amphotericin B and were associated with high in vitro antifungal activity. Liposomal amphotericin B was tolerated much better than the deoxycholate preparation. These findings suggest that the liposomal amphotericin B preparation is superior in the treatment of fungemia in granulocytopenic patients, and that randomized trials are warranted.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2512139     DOI: 10.1007/bf01963781

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  10 in total

1.  High-performance liquid chromatographic determination of amphotericin B in human serum.

Authors:  C Brassinne; C Laduron; A Coune; J P Sculier; C Hollaert; N Collette; F Meunier
Journal:  J Chromatogr       Date:  1987-08-07

2.  A pharmacologic guide to the clinical use of amphotericin B.

Authors:  D D Bindschadler; J E Bennett
Journal:  J Infect Dis       Date:  1969-10       Impact factor: 5.226

3.  Amphotericin B encapsulated in liposomes administered to cancer patients.

Authors:  F Meunier; J P Sculier; A Coune; C Brassinne; C Heyman; C Laduron; N Collette; C Hollaert; D Bron; J Klastersky
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

Review 4.  Overview of medically important antifungal azole derivatives.

Authors:  R A Fromtling
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

5.  Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study.

Authors:  G Lopez-Berestein; V Fainstein; R Hopfer; K Mehta; M P Sullivan; M Keating; M G Rosenblum; R Mehta; M Luna; E M Hersh
Journal:  J Infect Dis       Date:  1985-04       Impact factor: 5.226

6.  Serum fungistatic and fungicidal activity in volunteers receiving antifungal agents.

Authors:  F Meunier
Journal:  Eur J Clin Microbiol       Date:  1986-02       Impact factor: 3.267

7.  Fungemia in the immunocompromised host. Changing patterns, antigenemia, high mortality.

Authors:  F Meunier-Carpentier; T E Kiehn; D Armstrong
Journal:  Am J Med       Date:  1981-09       Impact factor: 4.965

8.  Treatment of hepatosplenic candidiasis with liposomal-amphotericin B.

Authors:  G Lopez-Berestein; G P Bodey; L S Frankel; K Mehta
Journal:  J Clin Oncol       Date:  1987-02       Impact factor: 44.544

Review 9.  Azole antifungal agents: emphasis on new triazoles.

Authors:  M S Saag; W E Dismukes
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

10.  Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections.

Authors:  J P Sculier; A Coune; F Meunier; C Brassinne; C Laduron; C Hollaert; N Collette; C Heymans; J Klastersky
Journal:  Eur J Cancer Clin Oncol       Date:  1988-03
  10 in total
  2 in total

Review 1.  Lipid formulations of amphotericin B. Less toxicity but at what economic cost?

Authors:  J Tollemar; O Ringdén
Journal:  Drug Saf       Date:  1995-10       Impact factor: 5.606

Review 2.  Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics.

Authors:  R Janknegt; S de Marie; I A Bakker-Woudenberg; D J Crommelin
Journal:  Clin Pharmacokinet       Date:  1992-10       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.